Loading
ETV4 (ETS translocation variant 4) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer, Lung cancer, Pancreatic ductal adenocarcinoma and 1 more.
Transcriptional activator. Regulates the positioning of motor neurons within the lateral medial column of the spinal cord and controls the terminal arborisation of specific motor neuron axons within their target muscles. Required for the expression of CDH8 and SEMA3E in ETV4-expressing motor neurons and for the exclusion of CDH7 expression from these neurons.
CIViC holds 3 clinical evidence items and 0 assertions across 1 variant, naming Trametinib. Open Targets scores its association with cancer at 0.65 (direct and indirect evidence; datatypes literature 0.99, animal model 0.41, genetic association 0.23, somatic mutation 0.97). IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Neuroblastoma.
In plain words · ETV4 (ETS translocation variant 4) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer, Lung cancer, Pancreatic ductal adenocarcinoma and 1 more.
ETV4 (ETS translocation variant 4) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer, Lung cancer, Pancreatic ductal adenocarcinoma and 1 more.
Transcriptional activator. Regulates the positioning of motor neurons within the lateral medial column of the spinal cord and controls the terminal arborisation of specific motor neuron axons within their target muscles.
No product in this corpus aims at ETV4 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA ETV4: RNA low tissue specificity; high antibody staining in 9 normal tissues; highest cancer staining colorectal cancer (5 of 12 high). Distribution: 4 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Prostate cancer, Lung cancer (all types), Pancreatic ductal adenocarcinoma, Childhood cancers (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P43268; CIViC gene ETV4; IntOGen ETV4; Human Protein Atlas ETV4 tissue; Open Targets ENSG00000175832 associations
First described 1993. Earliest sequence paper UniProt cites for the protein: Higashino et al, Nucleic Acids Res, 1993, "Isolation of a cDNA encoding the adenovirus E1A enhancer binding protein: a new human member of the ets oncogene family". Source.
Sources: HGNC HGNC:3493 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P43268 (protein name, function text, keywords and locations (REST API)); CIViC gene ETV4 (3 evidence items, 0 assertions, 1 variants; diseases: Lung Cancer, Prostate Cancer, Pancreatic Cancer (GraphQL API, CC0)); Open Targets ENSG00000175832 (association with cancer (MONDO_0004992) 0.65; per-cancer scores at or above 0.5: prostate cancer 0.58 (GraphQL API, CC0)); IntOGen ETV4 (driver in 1 cohort (Act 1, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Transcriptional activator. Regulates the positioning of motor neurons within the lateral medial column of the spinal cord and controls the terminal arborisation of specific motor neuron axons within their target muscles. Required for the expression of CDH8 and SEMA3E in ETV4-expressing motor neurons and for the exclusion of CDH7 expression from these neurons. May play a role in keratinocyte differentiation. Location: Nucleus (UniProt). Locus 17q21.31 (HGNC).
RNA: low tissue specificity, detected in many normal tissues.
Medium: Adipose tissue, Adrenal gland, Appendix, Breast, Bronchus, Cerebellum, Cervix, Colon.
RNA cancer enhanced: Testicular Germ Cell Tumor 203 pTPM.
Medium only: carcinoid, glioma, pancreatic cancer, thyroid cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"ETV4" OR ABSTRACT:"ETV4" OR TITLE:"ETS variant transcription factor 4" OR ABSTRACT:"ETS variant transcription factor 4" OR TITLE:"ETS translocation variant 4" OR ABSTRACT:"ETS translocation variant 4" OR TITLE:"E1A-F" OR ABSTRACT:"E1A-F" OR TITLE:"E1AF" OR ABSTRACT:"E1AF" OR TITLE:"PEA3" OR ABSTRACT:"PEA3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ETV4, not a curated reading list.
Shares Neuroblastoma (paediatric), IntOGen, Pancreatic ductal adenocarcinoma, Prostate cancer.
Shares Neuroblastoma (paediatric), IntOGen, Lung cancer (all types).
Shares Neuroblastoma (paediatric), IntOGen, Open Targets Platform.
Shares Neuroblastoma (paediatric), IntOGen, Open Targets Platform, Pancreatic ductal adenocarcinoma.
Shares Neuroblastoma (paediatric), CIViC.
Shares Neuroblastoma (paediatric), IntOGen.
Shares Neuroblastoma (paediatric), IntOGen.
Shares Neuroblastoma (paediatric), Lung cancer (all types), Open Targets Platform.